Granted Patent B2

US 12,440,491 · App. 18/213,464 · Granted Oct 14, 2025

Inventors: John Gordon Allen (Newbury Park, CA); Jennifer Rebecca Allen (Newbury Park, CA); Ana Elena Minatti (Santa Monica, CA); Qiufen Xue (Thousand Oaks, CA); Ryan Paul Wurz (Newbury Park, CA); Christopher M. Tegley (Daly City, CA); Alexander J. Pickrell (Westlake Village, CA); Thomas T. Nguyen (Newbury Park, CA); Vu Van Ma (Oak Park, CA); Patricia Lopez (Woodland Hills, CA); Longbin Liu (Thousand Oaks, CA); David John Kopecky (Washington, DC); Michael J. Frohn (Thousand Oaks, CA); Ning Chen (Thousand Oaks, CA); Jian Jeffrey Chen (San Diego, CA); Aaron C. Siegmund (Ventura, CA); Albert Amegadzie (Westlake Village, CA); Nuria A. Tamayo (Newbury Park, CA); Shon Booker (Sherman Oaks, CA); Clifford Goodman (Calabasas, CA); Mary Walton (Camarillo, CA); Nobuko Nishimura (West Hills, CA); Youngsook Shin (Seoul, KR); Jonathan D. Low (Northridge, CA); Victor J. Cee (Thousand Oaks, CA); Anthony B. Reed (Newbury Park, CA); Hui-Ling Wang (Thousand Oaks, CA); Brian Alan Lanman (Woodland Hills, CA)

Assignee: Amgen Inc.

A61K31/517A61K31/4985A61K39/39558A61P35/00C07D403/04C07D471/04

Abstract

Claims (17)

1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound, wherein the compound is

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof; or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof; or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof; or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a pharmaceutically acceptable salt of the atropisomer thereof; or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a pharmaceutically acceptable salt of the atropisomer thereof; or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof; or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof; or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof; or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof, or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof, or

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof;

wherein the cancer is mediated by a KRAS G12C mutation; and

wherein the cancer is non-small cell lung cancer, small intestine cancer, appendix cancer, colorectal cancer, endometrial cancer, pancreatic cancer, skin cancer, gastric cancer, nasal cavity cancer, bile duct cancer, or brain cancer.

2. The method of claim 1 , wherein the cancer is non-small cell lung cancer.

3. The method of claim 1 , wherein the cancer is colorectal cancer.

4. The method of claim 1 , wherein the cancer is pancreatic cancer.

Assignments (1)

Continuity (4)

References Cited (400)